Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
ZURNAI® (nalmefene injection) is a sterile, pre-filled, single-dose auto-injector designed to deliver a dose of 1.5 mg nalmefene (provided as nalmefene hydrochloride) in 0.5 mL.
Nalmefene hydrochloride, an opioid antagonist, is a 6-methylene analogue of naltrexone. The molecular structure of nalmefene is presented below:
 |
Molecular Formula: C21H25NO3•HCl
Molecular Weight: 375.9, CAS# 58895-64-0
Chemical Name: 17-(Cyclopropylmethyl)-4,5α-epoxy-6-methylenemorphinan-3,14-diol, hydrochloride salt
Nalmefene is a white to off-white crystalline powder which is freely soluble in water up to 130 mg/mL and slightly soluble in chloroform up to 0.13 mg/mL, with a pKa of 7.63.
Each ZURNAI auto-injector delivers 1.5 mg nalmefene (equivalent to 1.7 mg nalmefene hydrochloride) in 0.5 mL solution. The pH range is 3.5 to 4.5.
The inactive ingredients in ZURNAI nalmefene injection include: hydrochloric acid to adjust pH; magnesium chloride, 4.7 mg; and water for injection.
ZURNAI is indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression.
ZURNAI is intended for immediate administration as emergency therapy in settings where opioids may be present.
ZURNAI is not a substitute for emergency medical care.
The recommended dose of ZURNAI in adults and pediatric patients aged 12 years and older is 1.5 mg delivered by intramuscular or subcutaneous injection into the anterolateral aspect of the thigh, through clothing if necessary.
Seek emergency medical assistance as soon as possible after administration of the first dose of ZURNAI. The requirement for repeat doses of ZURNAI depends upon the amount, type, and route of administration of the opioid being antagonized.
If the patient responds to ZURNAI and subsequently relapses back into respiratory depression before emergency assistance arrives, administer an additional dose of ZURNAI using a new auto-injector and continue surveillance of the patient.
If the desired response is not obtained after 2 to 5 minutes, administer an additional dose of ZURNAI using a new auto-injector. If there is still no response and additional doses are available, administer additional doses of ZURNAI every 2 to 5 minutes using a new ZURNAI auto-injector for each dose until emergency medical assistance arrives.
Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.
Reversal of respiratory depression by partial agonists or mixed agonist/antagonists, such as buprenorphine and pentazocine, may be incomplete and require repeated administration of ZURNAI using a new auto-injector [see WARNINGS AND PRECAUTIONS].
Injection: 1.5 mg/0.5 mL nalmefene (base), clear, colorless to light yellow solution in a prefilled, single-dose auto-injector. Each ZURNAI auto-injector delivers 1.5 mg nalmefene (base) injection (0.5 mL).
Each single-dose auto-injector delivers 1.5 mg of nalmefene in 0.5 mL. Each carton contains one single-dose ZURNAI (nalmefene injection).
NDC 59011-962-01: One carton containing one single-dose auto-injector.
ZURNAI is not made with natural rubber latex.
Store at controlled room temperature 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F).
During storage, check ZURNAI through the viewing window of the auto-injector every 30 days.
The liquid should be clear, colorless to light yellow. If the ZURNAI liquid is discolored, cloudy, or contains solid particles, replace it with a new ZURNAI.
DO NOT FREEZE OR REFRIGERATE. Store in a clean dry place. Protect from light.
Keep ZURNAI in the carton until use.
Store ZURNAI securely and dispose of properly in a sharps container. For detailed disposal instructions, see the INSTRUCTIONS FOR USE.
KEEP ZURNAI AND ALL MEDICINES OUT OF THE REACH OF CHILDREN.
Before using, check to make sure the solution in the auto-injector is not discolored. Replace ZURNAI if the solution is discolored or contains a precipitate.
Each ZURNAI can only be used one time and cannot be re-used.
Manufactured for Purdue Pharma L.P., Stamford CT, 06901-3431. Revised: Aug 2024.
The following serious adverse reactions are described elsewhere in the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of ZURNAI is supported by pharmacokinetic and pharmacodynamic studies of ZURNAI in healthy subjects in a normal state and under steady state opioid agonism. The following adverse reactions were observed.
In a pharmacokinetic study (NAL1005) of 21 healthy adult volunteers exposed to one dose of ZURNAI the most common adverse reactions were: dizziness and headache.
In a pharmacodynamic study (NAL1004) of 23 healthy adult volunteers exposed to one dose of ZURNAI, the most common adverse reactions were: feeling hot, chills, nausea, allodynia, and headache.
Table 1: Relative Frequencies of Most Common Adverse Reactions that Occurred in Greater than 5% of Subjects in Study NAL1004 and Study NAL1005
| System Organ Class Preferred Term |
Nalmefene Auto-Injector 1.5 mg IM | ||
| Pooled NAL1004 and NAL1005 N=44 n (%) |
Study NAL1004 N=23 n (%) |
Study NAL1005 N=21 n (%) |
|
| Any AR | 28 (63.6) | 21 (91.3) | 7 (33.3) |
| Cardiac disorders | |||
| Palpitations | 4 (9.1) | 4 (17.4) | 0 |
| Ear and labyrinth disorders | |||
| Tinnitus | 4 (9.1) | 4 (17.4) | 0 |
| Ear discomfort | 3 (6.8) | 3 (13.0) | 0 |
| Gastrointestinal disorders | |||
| Nausea | 8 (18.2) | 6 (26.1) | 2 (9.5) |
| Vomiting | 5 (11.4) | 3 (13.0) | 2 (9.5) |
| General disorders and administration site conditions | |||
| Feeling hot | 11 (25.0) | 11 (47.8) | 0 |
| Chills | 6 (13.6) | 6 (26.1) | 0 |
| Feeling abnormal | 3 (6.8) | 3 (13.0) | 0 |
| Nervous system disorders | |||
| Dizziness | 7 (15.9) | 4 (17.4) | 3 (14.3) |
| Headache | 8 (18.2) | 5 (21.7) | 3 (14.3) |
| Allodynia | 5 (11.4) | 5 (21.7) | 0 |
| Burning sensation | 3 (6.8) | 3 (13.0) | 0 |
| Psychiatric disorders | |||
| Irritability | 3 (6.8) | 3 (13.0) | 0 |
| Vascular disorders | |||
| Hot flush | 3 (6.8) | 3 (13.0) | 0 |
Adverse reaction information was obtained following administration of nalmefene hydrochloride injection to 152 healthy volunteers and to 1127 patients in controlled clinical trials for the treatment of opioid overdose or for postoperative opioid reversal.
TABLE 2: Relative Frequencies of Common Adverse Reactions with an Incidence Greater than 1% (all patients, all clinical settings)
| Adverse Reaction | Nalmefene N=1127 |
Placebo N=77 |
| Nausea | 18% | 6% |
| Vomiting | 9% | 4% |
| Tachycardia | 5% | - |
| Hypertension | 5% | - |
| Postoperative pain | 4% | N/A |
| Fever | 3% | - |
| Dizziness | 3% | 1% |
| Headache | 1% | 4% |
| Chills | 1% | - |
| Hypotension | 1% | - |
| Vasodilatation | 1% | - |
CARDIOVASCULAR: Bradycardia, Arrhythmia
DIGESTIVE: Diarrhea, dry mouth
NERVOUS SYSTEM: Somnolence, depression, agitation, nervousness, tremor, confusion, withdrawal syndrome, myoclonus
RESPIRATORY: Pharyngitis
SKIN: Pruritus
UROGENITAL: Urinary retention
The incidence of adverse events was highest in patients who received more than the recommended dose of nalmefene hydrochloride injection.
The following adverse reactions have been identified during post-approval use of nalmefene. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Abrupt reversal of opioid depression using nalmefene in both postoperative and emergency department settings has resulted in nausea, vomiting, sweating, tremulousness, seizures, and cardiovascular instability including tachycardia, hypotension, hypertension, ventricular tachycardia and fibrillation, pulmonary edema, and cardiac arrest. Death, coma, and encephalopathy have been reported as sequelae of these events. These events have primarily occurred in patients who had pre-existing cardiovascular disorders or received other drugs that may have similar adverse cardiovascular effects.
In persons who were physically dependent on opioids, abrupt reversal of opioid effects has precipitated an acute withdrawal syndrome. Signs and symptoms have included: body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shiver or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, tachycardia. In some patients, there may be aggressive behavior upon abrupt reversal of an opioid overdose. In the neonate, opioid withdrawal symptoms also included convulsions, excessive crying, and hyperactive reflexes.
No Information Provided
Included as part of the "PRECAUTIONS" Section
Respiratory depression in the community overdose setting may be complex and involve the effects of multiple or unknown drugs, some of which may be long-acting opioids. While the duration of action of nalmefene is as long as most opioids, a recurrence of respiratory depression is possible, even after an apparently adequate initial response to ZURNAI treatment [see CLINICAL PHARMACOLOGY]. Therefore, it is necessary to seek emergency medical assistance immediately after administration of the first dose of ZURNAI and to keep the patient under continued surveillance. A second dose may be necessary if there is recurrence of symptoms of opioid overdose. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance [see DOSAGE AND ADMINISTRATION].
Reversal of respiratory depression by partial agonists or mixed agonist/antagonists such as buprenorphine and pentazocine, may be incomplete. Repeat doses of ZURNAI may be required to antagonize buprenorphine because the latter has a long duration of action due to its slow rate of binding and subsequent slow dissociation from the opioid receptor [see DOSAGE AND ADMINISTRATION]. Buprenorphine antagonism is characterized by a gradual onset of the reversal effects and a decreased duration of action of the normally prolonged respiratory depression.
The use of ZURNAI in patients who are opioid dependent may precipitate opioid withdrawal characterized by the following signs and symptoms: body aches, diarrhea, tachycardia, fever, runny nose, sneezing, piloerection, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, abdominal cramps, weakness, and increased blood pressure.
Abrupt postoperative reversal of opioid depression after using ZURNAI may result in nausea, vomiting, sweating, tremulousness, tachycardia, hypotension, hypertension, seizures, ventricular tachycardia and fibrillation, pulmonary edema, and cardiac arrest. Death, coma, and encephalopathy have been reported as sequelae of these events. These events have primarily occurred in patients who had pre-existing cardiovascular disorders or received other drugs that may have similar adverse cardiovascular effects. After use of ZURNAI, monitor patients with pre-existing cardiac disease or patients who have received medications with potential adverse cardiovascular effects for hypotension, ventricular tachycardia or fibrillation, and pulmonary edema in an appropriate healthcare setting. It has been suggested that the pathogenesis of pulmonary edema associated with the use of nalmefene is similar to neurogenic pulmonary edema, i.e., a centrally mediated massive catecholamine response leading to a dramatic shift of blood volume into the pulmonary vascular bed resulting in increased hydrostatic pressures.
ZURNAI is not indicated for use in patients less than 12 years of age. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may include the following signs and symptoms: convulsions, excessive crying, and hyperactive reflexes. Monitor the patient for the development of the signs and symptoms of opioid withdrawal. There may be clinical settings, particularly the postpartum period in neonates with known or suspected exposure to maternal opioid use, where it is preferable to avoid the abrupt precipitation of opioid withdrawal symptoms. In these settings, use an alternative, opioid antagonist product that can be titrated to effect and, where applicable, dosed according to weight [see Use In Specific Populations].
ZURNAI is unlikely to produce acute withdrawal symptoms in non-opioid dependent patients. The use of ZURNAI in patients who are opioid dependent may precipitate opioid withdrawal. Attempting to overcome opioid withdrawal symptoms caused by opioid antagonists with high or repeated doses of exogenous opioids could lead to opioid intoxication and death.
Inform patients of the potential consequences of trying to overcome the opioid blockade. Get emergency medical assistance as soon as possible after use of ZURNAI regardless of withdrawal symptoms.
Advise the patient and family members or caregivers to read the FDA-approved patient labeling (PATIENT INFORMATION and Instructions for Use).
Instruct patients and their family members or caregivers to become familiar with all information contained in the carton as soon as they receive ZURNAI.
Instruct patients and their family members or caregivers about how to recognize the signs and symptoms of an opioid overdose such as the following:
While the duration of action of nalmefene is as long as most opioids, instruct patients and their family members or caregivers that they must seek immediate emergency medical assistance after administration of the first dose of ZURNAI and keep the patient under continued surveillance even after an apparently adequate initial response to ZURNAI. A second dose may be necessary if there is recurrence of symptoms of opioid overdose [see DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS].
Instruct patients and their family members or caregivers that the reversal of respiratory depression caused by partial agonists or mixed agonist/antagonists, such as buprenorphine and pentazocine, may be incomplete and may require repeated administration of ZURNAI, using a new ZURNAI auto-injector each time [see DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS].
Instruct patients and their family members or caregivers that the use of ZURNAI in patients who are opioid dependent may precipitate opioid withdrawal [see WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS].
Instruct patients and their family member or caregivers to:
Healthcare professionals can telephone Purdue Pharma’s Medical Information Department (1- 888-726-7535) for information on this product.
Long-term animal studies to evaluate the carcinogenic potential of nalmefene have not been completed.
Nalmefene did not have mutagenic activity in the Ames test with five bacterial strains or the mouse lymphoma assay. Clastogenic activity was not observed in the mouse micronucleus test or in the cytogenic bone marrow assay in rats. However, nalmefene did exhibit a weak but significant clastogenic activity in the human lymphocyte metaphase assay in the absence but not in the presence of exogenous metabolic activation.
Oral administration of nalmefene up to 1200 mg/m2/day did not affect fertility in rats.
Life-sustaining therapy for opioid overdose should not be withheld (see Clinical Considerations). There are no available data on nalmefene use in pregnant women to evaluate for a drugassociated risk of major birth defects or miscarriage. In animal reproduction studies, no effects on embryo-fetal development were observed in rats and rabbits treated with nalmefene. [see Data]
The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Disease-associated maternal and/or embryo/fetal risk
An opioid overdose is a medical emergency and can be fatal for the pregnant woman and fetus if left untreated. Treatment with ZURNAI for opioid overdose should not be withheld because of potential concerns regarding the effects of ZURNAI on the fetus.
Animal Data
Reproduction studies have been performed in rats and rabbits by oral administration and in rabbits by intravenous administration of nalmefene. No effects on embryo-fetal development were observed at rat oral doses up to 1200 mg/m2/day and rabbit oral doses up to 2400 mg/m2/day, and intravenous dose up to 96 mg/m2/day, which is 52 times the human dose of 3.0 mg (two ZURNAI administrations) based on body surface area comparison. The treatment in rats did not affect offspring survival.
There are no data on the presence of nalmefene and its metabolites in human milk, the effects of nalmefene on the breastfed child, or the effects on milk production. Nalmefene and its metabolites are present in rat milk (see Data). When a drug is present in animal milk, it is likely that the drug will be present in human milk.
Nalmefene and its metabolites were secreted into rat milk, reaching concentrations approximately three times those in plasma at one hour and decreasing to about half the corresponding plasma concentrations by 24 hours following bolus administration. The concentration of nalmefene in animal milk does not necessarily predict the concentration of drug in human milk.
The safety and effectiveness of ZURNAI for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, have been established in pediatric patients aged 12 years and older.
Use for this indication in this age group is supported by adult studies and pharmacokinetic simulation [see CLINICAL PHARMACOLOGY]. There have been no studies conducted to evaluate the use of ZURNAI in pediatric patients.
The safety and effectiveness of ZURNAI for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, have not been established in pediatric patients younger than 12 years of age.
Clinical studies of nalmefene hydrochloride injection did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. Geriatric patients have a greater frequency of decreased hepatic, renal, or cardiac function, or other drug therapy. Therefore, the systemic exposure of nalmefene can be higher in these patients.
Hepatic impairment substantially reduces the clearance of nalmefene [see CLINICAL PHARMACOLOGY]. For single episodes of opioid antagonism, adjustment of ZURNAI dosage is not required.
Renal impairment substantially reduces the clearance of nalmefene [see CLINICAL PHARMACOLOGY]. For single episodes of opioid antagonisms, adjustment of ZURNAI dosage is not required.
No Information Provided
ZURNAI is contraindicated in patients known to be hypersensitive to nalmefene hydrochloride or to any other ingredients in the product.
ZURNAI is an antagonist at opioid receptors.
Nalmefene reverses the effects of natural and synthetic opioids, including respiratory depression, sedation, and hypotension. Pharmacodynamic studies have shown that nalmefene injection has a longer duration of action than naloxone injection at fully reversing doses. Nalmefene has no opioid agonist activity.
The effect of ZURNAI was studied in an experimental clinical opioid-induced respiratory depression (OIRD) model in twenty-four opioid-experienced, non-opioid dependent subjects (NAL1004). This model assessed changes in minute ventilation (MV) during administration of a 3-step intravenous fentanyl infusion. In step 1, fentanyl was infused until MV nadir (functional OIRD) was achieved. MV nadir was defined as a 50% reduction in MV from baseline or the MV reduction achieved following the maximum permitted fentanyl titration. Following attainment of MV nadir, the fentanyl infusion rate was decreased (step 2) to maintain the fentanyl concentrations. ZURNAI was administered at 10 minutes following MV nadir. Ten minutes following ZURNAI administration, the fentanyl infusion rate was further decreased (step 3) to maintain constant fentanyl concentrations for the remaining duration of the reversal session.
Following ZURNAI administration the time to onset of effect, that is onset of reversal of respiratory depression, was observed between 2.5 to 5 minutes (Figure 1 and Figure 2). At 5 minutes mean change in MV from nadir was 4.42 L/min (Figure 1). Full recovery of respiratory drive was noted between 5 and 15 minutes after ZURNAI administration (Figure 1 and Figure 2).
Figure 1: Reversal of Fentanyl-Induced Respiratory Depression in adult healthy volunteers treated with ZURNAI (nalmefene)
 |
Figure 2: Percent Recovery of Respiratory Drive after Fentanyl Infusion in Minute Ventilation (Mean SD) in Adult Healthy Volunteers with ZURNAI 1.5 mg
 |
Nalmefene is not known to produce respiratory depression, psychotomimetic effects, or pupillary constriction. No pharmacological activity was observed when nalmefene was administered in the absence of opioid agonists.
Nalmefene has not been shown to produce tolerance, physical dependence, or abuse potential.
Nalmefene can produce acute withdrawal symptoms in individuals who are opioid dependent.
In a pharmacokinetic study (NAL1005) in 24 healthy adult subjects, the relative bioavailability of one dose of ZURNAI administered intramuscularly was compared to a single dose of nalmefene 1.0 mg administered as an intramuscular injection. The pharmacokinetic parameters obtained in this study are shown in Table 3 and the plasma concentration time profiles of nalmefene are presented in Figure 3.
Table 3: Geometric Mean (CV%) Nalmefene PK Parameters after Administration of 1.5 mg ZURNAI Intramuscular (IM), 1.0 mg Nalmefene IM, and 1.0 mg Nalmefene Intravenous (IV)
| Parameter | ZURNAI 1.5 mg |
Nalmefene IM 1.0 mg |
Nalmefene IV 1.0 mg |
| Tmax (h)a | 0.25 (0.083-1.00) | 0.50 (0.083-2.00) | 0.083 (0.083 -0.25) |
| Cmax (ng/mL) | 7.37 (47.5) | 2.39 (32.6) | 6.94 (55.7) |
| AUC0-2.5min (ng-hr/mL) b | 0.011 (288) | 0.001 (241) | 0.062 (56.1) |
| AUC0-5min (ng-hr/mL) b | 0.077 (144) | 0.010 (209) | 0.299 (40.4) |
| AUC0-10min (ng-hr/mL) | 0.320 (85.8) | 0.047 (107) | 0.768 (46.2) |
| AUC0-15min (ng-hr/mL) | 0.831 (62.7) | 0.152 (64.8) | 1.16 (46.1) |
| AUC0-20min (ng-hr/mL) | 1.31 (51.3) | 0.315 (48.3) | 1.50 (41.7) |
| AUC0-30min (ng-hr/mL) | 2.24 (39.3) | 0.647 (40.7) | 2.07 (34.0) |
| AUC0-inf (ng-hr/mL) | 30.53 (16.0) | 17.98 (21.0) | 18.22 (15.3) |
| Frel (%)b | 113 (13.0) | NA | NA |
| T½ (h) b | 9.07 (26.6) | 7.74 (24.3) | 9.12 (16.5) |
| a Tmax presented as median (range) b Arithmetic mean NA Not applicable. |
|||
Figure 3: Mean Plasma Concentration-Time Profiles of Nalmefene (a) 0-12 hours and (b) 0-60 minutes Following Administration of 1.5 mg ZURNAI Intramuscular (IM), 1.0 mg Nalmefene IM, and 1.0 mg Nalmefene Intravenous (IV)
 |
 |
After administration of one ZURNAI to healthy adult subjects, the median Tmax for ZURNAI was 0.250 hours, compared to 0.5 hours for the intramuscular nalmefene 1 mg injection.
Based on dose-normalized area under the curve (AUCinf), the mean bioavailability of ZURNAI was 1.13 (Frel) relative to intramuscular administration of nalmefene 1 mg and was 1.15 (Fabs) relative to intravenous administration of nalmefene 1 mg.
Following a 1 mg parenteral dose, nalmefene was rapidly distributed. In a study of brain receptor occupancy, a 1 mg dose of nalmefene blocked over 80% of brain opioid receptors within 5 minutes after administration. The apparent volumes of distribution centrally (Vc) and at steady state (Vdss) are 3.9 ± 1.1 L/kg and 8.6 ± 1.7 L/kg, respectively. Ultrafiltration studies of nalmefene have demonstrated that 45% (CV 4.1%) is bound to plasma proteins over a concentration range of 0.1 to 2 mcg/mL. An in vitro determination of the distribution of nalmefene in human blood demonstrated that nalmefene distributed 67% (CV 8.7%) into red blood cells and 39% (CV 6.4%) into plasma. The whole blood to plasma ratio was 1.3 (CV 6.6%) over the nominal concentration range in whole blood from 0.376 to 30 ng/mL.
After administration of ZURNAI to healthy adult subjects, plasma concentrations have a terminal elimination half-life of 9.07 (%CV 26.2) hours. Following a 1 mg parenteral dose, the apparent clearance of nalmefene is 55.46 (%CV 8.41) L/hr.
Metabolism
Nalmefene is metabolized by the liver, primarily by glucuronide conjugation.
Nalmefene is also metabolized to trace amounts of an N-dealkylated metabolite. Nalmefene glucuronide is inactive and the N-dealkylated metabolite has minimal pharmacological activity.
Excretion
Nalmefene and its metabolites are excreted in the urine. Less than 5% of nalmefene is excreted in the urine unchanged. Seventeen percent (17%) of the nalmefene dose is excreted in the feces.
The plasma concentration-time profile in some subjects suggests that nalmefene undergoes enterohepatic recycling.
In previous studies with nalmefene hydrochloride injection, dose proportionality was observed in nalmefene AUC0-inf following 0.5 to 2 mg intravenous administration to elderly male subjects.
Following a 1 mg intravenous nalmefene dose, there were no significant differences between young (19 to 32 years) and elderly (62 to 80 years) adult male subjects with respect to plasma clearance, steady-state volume of distribution, or half-life. There was an apparent age-related decrease in the central volume of distribution (young: 3.9 ± 1.1 L/kg, elderly: 2.8 ± 1.1 L/kg) that resulted in a greater initial nalmefene concentration in the elderly group. While initial nalmefene plasma concentrations were transiently higher in the elderly, it would not be anticipated that this population would require dosing adjustment. No clinical adverse events were noted in the elderly following the 1 mg intravenous nalmefene dose.
No pharmacokinetic studies were conducted with ZURNAI in pediatric patients. Based on population PK simulations, compared to an adult population (mean weight 76 kg), 12-year-old subjects with a median weight 49 kg, range 33 to 71 kg are expected to have 27% higher mean Cmax and 15% higher mean AUC0-∞ [see Use In Specific Populations].
There is insufficient experience with the use of nalmefene hydrochloride injection to detect sex variations in pharmacokinetics.
The pharmacokinetics of ZURNAI have not been studied in renally impaired subjects. In previous studies with nalmefene hydrochloride injection in there was a statistically significant 27% decrease in plasma clearance of nalmefene in the end-stage renal disease (ESRD) population during interdialysis (0.57 ± 0.20 L/hr/kg) and a 25% decreased plasma clearance in the ESRD population during intradialysis (0.59 ± 0.18 L/hr/kg) compared to normal patients (0.79 ± 0.24 L/hr/kg). The elimination half-life was prolonged in ESRD patients from 10.2 ± 2.2 hours in normal patients to 26.1 ± 9.9 hours.
The pharmacokinetics of ZURNAI have not been studied in hepatically impaired subjects. In previous studies with nalmefene hydrochloride injection in subjects with hepatic disease, when compared to matched normal controls, had a 28.3% decrease in plasma clearance of nalmefene (0.56 ± 0.21 L/hr/kg versus 0.78 ± 0.24 L/hr/kg, respectively). Elimination half-life increased from 10.2 ± 2.2 hours to 11.9 ± 2.0 hours in the hepatically impaired. No dosage adjustment is recommended since nalmefene will be administered as an acute course of therapy.
The effect of weight on nalmefene PK following a single dose of 1.5 mg ZURNAI administration was assessed using population pharmacokinetic simulations. Compared to the mean PK values across the full population in the PK dataset (median weight 76 kg), the 1st quartile of body weight (54.0 to 67.3 kg) had + 17.6% higher Cmax and + 13.4% higher AUC0-∞ whereas the 4th quartile of body weight (86.8 to 117.1 kg) had – 15.3% lower Cmax and – 11.8% lower AUC0-∞.
ZURNAI
(zur nye)
(nalmefene injection)
You and your family members or caregivers should read this Patient Information leaflet before an opioid emergency happens. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.
What is the most important information I should know about ZURNAI?
ZURNAI is used to temporarily reverse the effects of opioid medicines. The medicine in ZURNAI is not expected to have an effect in people who are not taking opioid medicines. Always carry ZURNAI with you in case of an opioid emergency.
What is ZURNAI?
It is not known if ZURNAI is safe and effective in children younger than 12 years of age for the emergency treatment of known or suspected opioid overdose.
Do not use ZURNAI if you are allergic to nalmefene hydrochloride or any of the ingredients in ZURNAI. See the end of this Patient Information leaflet for a complete list of ingredients in ZURNAI.
Before using ZURNAI, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How should I use ZURNAI?
Read the “Instructions for Use” at the end of this Patient Information leaflet for detailed information about the right way to use ZURNAI.
What are the possible side effects of ZURNAI?
ZURNAI may cause serious side effects, including:
The most common side effects of ZURNAI include:
These are not all of the possible side effects of ZURNAI.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store ZURNAI?
Keep ZURNAI and all medicines out of the reach of children.
General information about the safe and effective use of ZURNAI.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ZURNAI for a condition for which it was not prescribed. You can ask your pharmacist or healthcare provider for information about ZURNAI that is written for health professionals.
What are the ingredients in ZURNAI?
Active ingredient: nalmefene
Inactive ingredients: hydrochloric acid to adjust pH, magnesium chloride, and water for injection.
ZURNAI is not made with natural rubber latex.
Manufactured for: Purdue Pharma L.P., Stamford, CT 06901-3431.
This Patient Information has been approved by the U.S. Food and Drug Administration.
INSTRUCTIONS FOR USE
ZURNAI
(zur nye)
(nalmefene injection)
The Instructions for Use contains information on how to give ZURNAI in response to a known or suspected opioid overdose in adults and children 12 years of age and older. You and your family members or caregivers should read the Instructions for Use that comes with ZURNAI before using it. Talk to your healthcare provider if you and your family members or caregivers have any questions about the use of ZURNAI.
ZURNAI auto-injector parts:
 |
Important information you need to know before injecting ZURNAI
Preparing to inject ZURNAI
Injecting ZURNAI
1. Remove the blue cap
 |
2. Position and inject
 |
3. Inspect the viewing window
 |
4. Call 911 and watch the person
 |
 |
 |
5. Throw away (dispose of) the used ZURNAI auto-injector
Disposing of (throwing away) ZURNAI
 |
Important: Always keep the sharps disposal container out of the reach of children.
Storing ZURNAI
Keep ZURNAI and all medicines out of the reach of children.
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
